Title: The Phosphatidylinositol 3-Kinase (PI3K)-Akt Pathway Suppresses Bax Translocation to Mitochondria
Abstract: Bax, a proapoptotic member of the Bcl-2 family, localizes largely in the cytoplasm but redistributes to mitochondria in response to apoptotic stimuli, where it induces cytochromec release. In this study, we show that the phosphatidylinositol 3-OH kinase (PI3K)-Akt pathway plays an important role in the regulation of Bax subcellular localization. We found that LY294002, a PI3K inhibitor, blocked the effects of serum to prevent Bax translocation to mitochondria and that expression of an active form of PI3K suppressed staurosporine-induced Bax translocation, suggesting that PI3K activity is essential for retaining Bax in the cytoplasm. In contrast, both U0126, a MEK inhibitor, and active MEK had little effect on Bax localization. In respect to downstream effectors of PI3K, we found that expression of active Akt, but not serum and glucocorticoid-induced protein kinase (SGK), suppressed staurosporine-induced translocation of Bax, whereas dominant negative Akt moderately promoted Bax translocation. Expression of Akt did not alter the levels of Bax, Bcl-2, Bcl-XL, or phosphorylated JNK under the conditions used, suggesting that there were alternative mechanisms for Akt in the suppression of Bax translocation. Collectively, these results suggest that the PI3K-Akt pathway inhibits Bax translocation from cytoplasm to mitochondria and have revealed a novel mechanism by which the PI3K-Akt pathway promotes survival. Bax, a proapoptotic member of the Bcl-2 family, localizes largely in the cytoplasm but redistributes to mitochondria in response to apoptotic stimuli, where it induces cytochromec release. In this study, we show that the phosphatidylinositol 3-OH kinase (PI3K)-Akt pathway plays an important role in the regulation of Bax subcellular localization. We found that LY294002, a PI3K inhibitor, blocked the effects of serum to prevent Bax translocation to mitochondria and that expression of an active form of PI3K suppressed staurosporine-induced Bax translocation, suggesting that PI3K activity is essential for retaining Bax in the cytoplasm. In contrast, both U0126, a MEK inhibitor, and active MEK had little effect on Bax localization. In respect to downstream effectors of PI3K, we found that expression of active Akt, but not serum and glucocorticoid-induced protein kinase (SGK), suppressed staurosporine-induced translocation of Bax, whereas dominant negative Akt moderately promoted Bax translocation. Expression of Akt did not alter the levels of Bax, Bcl-2, Bcl-XL, or phosphorylated JNK under the conditions used, suggesting that there were alternative mechanisms for Akt in the suppression of Bax translocation. Collectively, these results suggest that the PI3K-Akt pathway inhibits Bax translocation from cytoplasm to mitochondria and have revealed a novel mechanism by which the PI3K-Akt pathway promotes survival. Apoptosis plays a critical role in the normal development and maintenance of tissue homeostasis (1.Hengartner M.O. Nature. 2000; 407: 770-776Crossref PubMed Scopus (6377) Google Scholar, 2.Meier P. Finch A. Evan G. Nature. 2000; 407: 796-801Crossref PubMed Scopus (837) Google Scholar). The regulation of mitochondrial membrane integrity and the release of cytochromec from mitochondria are important processes during apoptosis (3.Green D.R. Reed J.C. Science. 1998; 281: 1309-1312Crossref PubMed Google Scholar, 4.Kroemer G. Reed J.C. Nat. Med. 2000; 6: 513-519Crossref PubMed Scopus (2821) Google Scholar) and are controlled by the Bcl-2 family (5.Gross A. McDonnell J.M. Korsmeyer S.J. Genes Dev. 1999; 13: 1899-1911Crossref PubMed Scopus (3289) Google Scholar, 6.Vander Heiden M.G. Thompson C.B. Nat. Cell Biol. 1999; 1: E209-E216Crossref PubMed Scopus (605) Google Scholar). The Bcl-2 family includes both pro- and antiapoptotic members that possess up to four conserved Bcl-2 homology domains designated BH1, BH2, BH3, and BH4 (5.Gross A. McDonnell J.M. Korsmeyer S.J. Genes Dev. 1999; 13: 1899-1911Crossref PubMed Scopus (3289) Google Scholar,6.Vander Heiden M.G. Thompson C.B. Nat. Cell Biol. 1999; 1: E209-E216Crossref PubMed Scopus (605) Google Scholar). Many of the antiapoptotic members, including Bcl-2 and Bcl-XL, contain all four domains, whereas the proapoptotic members, including Bax and Bak, lack the BH4 domain, and the other proapoptotic members, so-called “BH3 domain only proteins,” including Bid, Bim and Bad, contain only the BH3 domain. One of the intriguing aspects of the Bcl-2 family is their subcellular localization and translocation. For example, antiapoptotic members such as Bcl-2 and Bcl-XL and proapoptotic members such as Bak localize predominantly at mitochondria and regulate the mitochondrial membrane integrity and cytochrome c release. On the other hand, other proapoptotic members such as Bax, Bid, and Bad reside in cytoplasm in healthy cells (5.Gross A. McDonnell J.M. Korsmeyer S.J. Genes Dev. 1999; 13: 1899-1911Crossref PubMed Scopus (3289) Google Scholar). In response to apoptotic stimuli, these cytosolic proapoptotic members redistribute to mitochondria and promote cytochrome c release. For example, active caspase-8 cleaves p22 Bid into p15 Bid, which translocates to mitochondria (7.Li H. Zhu H. Xu C.J. Yuan J. Cell. 1998; 94: 491-501Abstract Full Text Full Text PDF PubMed Scopus (3837) Google Scholar, 8.Luo X. Budihardjo I. Zou H. Slaughter C. Wang X. Cell. 1998; 94: 481-490Abstract Full Text Full Text PDF PubMed Scopus (3112) Google Scholar). For Bad, the localization is regulated by phosphorylation; survival signals induce phosphorylation of Bad, resulting in 14-3-3 binding and sequestration from its mitochondrial target, Bcl-XL (9.Datta S.R. Dudek H. Tao X. Masters S. Fu H. Gotoh Y. Greenberg M.E. Cell. 1997; 91: 231-241Abstract Full Text Full Text PDF PubMed Scopus (5003) Google Scholar,10.del Peso L. Gonzalez-Garcia M. Page C. Herrera R. Nunez G. Science. 1997; 278: 687-689Crossref PubMed Scopus (2000) Google Scholar). Therefore, the loss of survival signals translocates Bad to mitochondria through dephosphorylation (11.Wang H.G. Pathan N. Ethell I.M. Krajewski S. Yamaguchi Y. Shibasaki F. McKeon F. Bobo T. Franke T.F. Reed J.C. Science. 1999; 284: 339-343Crossref PubMed Scopus (975) Google Scholar, 12.Ayllon V. Martinez A.C. Garcia A. Cayla X. Rebollo A. EMBO J. 2000; 19: 2237-2246Crossref PubMed Scopus (123) Google Scholar). After translocation to mitochondria, Bax induces cytochromec release either by forming a pore through oligomerization or by opening a channel called voltage-dependent anion channel (VDAC) 1The abbreviations used are: VDACvoltage-dependent anion channelNGFnerve growth factorILinterleukinPI3Kphosphatidylinositol 3-OH kinaseMAPKmitogen-activated protein kinasePtdInsphosphatidylinositolSGKserum and glucocorticoid-induced protein kinaseMEKmitogen-activated protein kinase/extracellular signal-regulated kinase kinasePBSphosphate-buffered salineDTTdithiothreitolGFPgreen fluorescent proteinJNKc-Jun N-terminal kinasePDK3-phosphoinositide-dependent kinasevia direct interaction (13.Saito M. Korsmeyer S.J. Schlesinger P.H. Nat. Cell Biol. 2000; 2: 553-555Crossref PubMed Scopus (415) Google Scholar, 14.Shimizu S. Narita M. Tsujimoto Y. Nature. 1999; 399: 483-487Crossref PubMed Scopus (1939) Google Scholar). Bax translocation to mitochondria may serve as a key integration point for various apoptosis signals because Bax translocation takes place in response to a wide variety of apoptotic stimuli such as staurosporine, dexamethasone, etoposide, nitric oxide, Fas, cell detachment, and γ-irradiation (15.Hsu Y.T. Wolter K.G. Youle R.J. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 3668-3672Crossref PubMed Scopus (1045) Google Scholar, 16.Wolter K.G. Hsu Y.T. Smith C.L. Nechushtan A. Xi X.G. Youle R.J. J. Cell Biol. 1997; 139: 1281-1292Crossref PubMed Scopus (1586) Google Scholar, 17.Nomura M. Shimizu S. Ito T. Narita M. Matsuda H. Tsujimoto Y. Cancer Res. 1999; 59: 5542-5548PubMed Google Scholar, 18.Murphy K.M. Streips U.N. Lock R.B. J. Biol. Chem. 2000; 275: 17225-17228Abstract Full Text Full Text PDF PubMed Scopus (124) Google Scholar, 19.Ghatan S. Larner S. Kinoshita Y. Hetman M. Patel L. Xia Z. Youle R.J. Morrison R.S. J. Cell Biol. 2000; 150: 335-347Crossref PubMed Scopus (367) Google Scholar, 20.Gilmore A.P. Metcalfe A.D. Romer L.H. Streuli C.H. J. Cell Biol. 2000; 149: 431-446Crossref PubMed Scopus (256) Google Scholar) and because the essential roles of Bax in inducing apoptosis have been revealed by gene disruption of Bax alone (21.Knudson C.M. Tung K.S. Tourtellotte W.G. Brown G.A. Korsmeyer S.J. Science. 1995; 270: 96-99Crossref PubMed Scopus (1323) Google Scholar, 22.Deckwerth T.L. Elliott J.L. Knudson C.M. Johnson Jr., E.M. Snider W.D. Korsmeyer S.J. Neuron. 1996; 17: 401-411Abstract Full Text Full Text PDF PubMed Scopus (661) Google Scholar) and of both Bax and Bak (23.Lindsten T. Ross A.J. King A. Zong W.X. Rathmell J.C. Shiels H.A. Ulrich E. Waymire K.G. Mahar P. Frauwirth K. Chen Y. Wei M. Eng V.M. Adelman D.M. Simon M.C. Ma A. Golden J.A. Evan G. Korsmeyer S.J. MacGregor G.R. Thompson C.B. Mol. Cell. 2000; 6: 1389-1399Abstract Full Text Full Text PDF PubMed Scopus (1223) Google Scholar, 24.Wei M.C. Zong W.X. Cheng E.H. Lindsten T. Panoutsakopoulou V. Ross A.J. Roth K.A. MacGregor G.R. Thompson C.B. Korsmeyer S.J. Science. 2001; 292: 727-730Crossref PubMed Scopus (3407) Google Scholar, 25.Zong W.X. Lindsten T. Ross A.J. MacGregor G.R. Thompson C.B. Genes Dev. 2001; 15: 1481-1486Crossref PubMed Scopus (720) Google Scholar). Recent studies have shown that NGF treatment of sympathetic neurons (26.Putcha G.V. Deshmukh M. Johnson Jr., E.M. J. Neurosci. 1999; 19: 7476-7485Crossref PubMed Google Scholar) and IL-7 treatment of thymocytes (27.Khaled A.R. Kim K. Hofmeister R. Muegge K. Durum S.K. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 14476-14481Crossref PubMed Scopus (223) Google Scholar) inhibit Bax translocation to mitochondria, suggesting that some survival signals also regulate Bax translocation. However, how survival signals regulate Bax localization has yet to be clarified. voltage-dependent anion channel nerve growth factor interleukin phosphatidylinositol 3-OH kinase mitogen-activated protein kinase phosphatidylinositol serum and glucocorticoid-induced protein kinase mitogen-activated protein kinase/extracellular signal-regulated kinase kinase phosphate-buffered saline dithiothreitol green fluorescent protein c-Jun N-terminal kinase 3-phosphoinositide-dependent kinase It has been shown that the phosphatidylinositol 3-OH kinase (PI3K) pathway and the mitogen-activated protein kinase (MAPK) pathway play critical roles in promotion of cell survival (28.Datta S.R. Brunet A. Greenberg M.E. Genes Dev. 1999; 13: 2905-2927Crossref PubMed Scopus (3755) Google Scholar, 29.Bonni A. Brunet A. West A.E. Datta S.R. Takasu M.A. Greenberg M.E. Science. 1999; 286: 1358-1362Crossref PubMed Scopus (1697) Google Scholar, 30.Brunet A. Datta S.R. Greenberg M.E. Curr. Opin. Neurobiol. 2001; 11: 297-305Crossref PubMed Scopus (1026) Google Scholar, 31.Erhardt P. Schremser E.J. Cooper G.M. Mol. Cell. Biol. 1999; 19: 5308-5315Crossref PubMed Scopus (268) Google Scholar). PI3K phosphorylates the 3-OH position of the inositol ring in phosphatidylinositol (PtdIns), generating PtdIns(3,4)P2 and PtdIns(3,4,5)P3. Both PtdIns(3,4)P2 and PtdIns(3,4,5)P3 bind to the pleckstrin homology domain of PDK1, which in turn activates downstream targets such as Akt and SGK (32.Vanhaesebroeck B. Alessi D.R. Biochem. J. 2000; 346: 561-576Crossref PubMed Scopus (1408) Google Scholar, 33.Park J. Leong M.L. Buse P. Maiyar A.C. Firestone G.L. Hemmings B.A. EMBO J. 1999; 18: 3024-3033Crossref PubMed Scopus (489) Google Scholar). Akt inhibits apoptosis by inactivating proapoptotic proteins such as Bad, caspase-9, forkhead, and Nur77 and by activating antiapoptotic proteins such as NF-κB and cAMP-response element-binding protein (9.Datta S.R. Dudek H. Tao X. Masters S. Fu H. Gotoh Y. Greenberg M.E. Cell. 1997; 91: 231-241Abstract Full Text Full Text PDF PubMed Scopus (5003) Google Scholar, 10.del Peso L. Gonzalez-Garcia M. Page C. Herrera R. Nunez G. Science. 1997; 278: 687-689Crossref PubMed Scopus (2000) Google Scholar, 34.Cardone M.H. Roy N. Stennicke H.R. Salvesen G.S. Franke T.F. Stanbridge E. Frisch S. Reed J.C. Science. 1998; 282: 1318-1321Crossref PubMed Scopus (2752) Google Scholar, 35.Brunet A. Bonni A. Zigmond M.J. Lin M.Z. Juo P. Hu L.S. Anderson M.J. Arden K.C. Blenis J. Greenberg M.E. Cell. 1999; 96: 857-868Abstract Full Text Full Text PDF PubMed Scopus (5526) Google Scholar, 36.Masuyama N. Oishi K. Mori Y. Ueno T. Takahama Y. Gotoh Y. J. Biol. Chem. 2001; 276: 32799-32805Abstract Full Text Full Text PDF PubMed Scopus (138) Google Scholar, 37.Romashkova J.A. Makarov S.S. Nature. 1999; 401: 86-90Crossref PubMed Scopus (1687) Google Scholar, 38.Ozes O.N. Mayo L.D. Gustin J.A. Pfeffer S.R. Pfeffer L.M. Donner D.B. Nature. 1999; 401: 82-85Crossref PubMed Scopus (1927) Google Scholar, 39.Kane L.P. Shapiro V.S. Stokoe D. Weiss A. Curr. Biol. 1999; 9: 601-604Abstract Full Text Full Text PDF PubMed Scopus (748) Google Scholar, 40.Du K. Montminy M. J. Biol. Chem. 1998; 273: 32377-32379Abstract Full Text Full Text PDF PubMed Scopus (835) Google Scholar). Recent studies have suggested that Akt inhibits apoptosis at a premitochondrial level because it inhibits cytochrome c release and alteration of mitochondrial membrane potential (41.Kennedy S.G. Kandel E.S. Cross T.K. Hay N. Mol. Cell. Biol. 1999; 19: 5800-5810Crossref PubMed Scopus (602) Google Scholar, 42.Gottlob K. Majewski N. Kennedy S. Kandel E. Robey R.B. Hay N. Genes Dev. 2001; 15: 1406-1418Crossref PubMed Scopus (789) Google Scholar). However, the mechanisms by which Akt inhibits the premitochondrial events of apoptosis are not fully understood (41.Kennedy S.G. Kandel E.S. Cross T.K. Hay N. Mol. Cell. Biol. 1999; 19: 5800-5810Crossref PubMed Scopus (602) Google Scholar). In this study, we asked which molecules activated by growth factors are responsible for regulation of Bax subcellular localization. We found that PI3K activity is essential for retaining Bax in the cytoplasm and also demonstrated that Akt, but not SGK, is capable of suppressing Bax translocation to mitochondria. These results suggest that the PI3K-Akt pathway plays a critical role in inhibiting Bax translocation to mitochondria. We obtained LY294002 from Calbiochem, U0126 from Promega, staurosporine from ICN Biomedicals, MitoTracker CMXRos, Hoechst33258, and Hoechst33342 from Molecular Probes, and Z-VAD-CH2DCB from Phoenix Pharmaceuticals Inc. Anti-Bax (N-20, Santa Cruz Biotechnology), anti-VDAC (31HL, Calbiochem), anti-MAPK (K-23, Santa Cruz Biotechnology), anti-phospho-MAPK (Promega), anti-Akt (Cell Signaling), anti-phospho-Akt (Cell Signaling), anti-tubulin (DM1A, Sigma), anti-Bcl-2 (Bcl-2/100, PharMingen), anti-Bcl-XL (L-19, Santa Cruz Biotechnology), anti-FKHRL1 (H-144, Santa Cruz Biotechnology), anti-phospho-FKHRL1 (Cell Signaling), anti-HA (3F10, Roche Molecular Biochemicals), anti-JNK (C-17, Santa Cruz Biotechnology), and anti-phospho-JNK (Cell Signaling) were used for immunoblotting, and anti-Bax (G206–1276 PharMingen) and Alexa-488 anti-rat IgG (Molecular Probes) were used for immunocytochemistry. Mouse Bax cDNA was amplified by PCR and cloned into EcoRI and KpnI sites of pEGFP-C2 vector (CLONTECH). The constructs encoding p35, constitutively active Akt (myristylated Akt lacking the pleckstrin homology domain, residues 4–125), dominant negative (3A) Akt with a K179A/T308A/S473A mutation, p110CAAX (the membrane-targeted catalytic subunit of PI3K), constitutively active MEK with a S218D/S222D mutation, constitutively active SGK with a S422D mutation, dominant negative (2A) SGK with a T256A/S422A mutation, and FKHRL1 have been described previously (33.Park J. Leong M.L. Buse P. Maiyar A.C. Firestone G.L. Hemmings B.A. EMBO J. 1999; 18: 3024-3033Crossref PubMed Scopus (489) Google Scholar, 43.Kanuka H. Hisahara S. Sawamoto K. Shoji S. Okano H. Miura M. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 145-150Crossref PubMed Scopus (39) Google Scholar, 44.Brunet A. Park J. Tran H. Hu L.S. Hemmings B.A. Greenberg M.E. Mol. Cell. Biol. 2001; 21: 952-965Crossref PubMed Scopus (724) Google Scholar). Active and 2A SGK clones were inserted into the BglII site of pCS4-HA. DsRed-Mit was constructed by inserting synthetic double-stranded oligonucleotides spanning a mitochondrial targeting sequence of human cytochrome c oxidase into BamHI and NheI sites of the pDsRed-N1 vector (CLONTECH). HeLa cells were incubated with 50 μm Z-VAD-CH2DCB in the absence of serum for 6 h, treated with or without 10 μm LY294002 or 10 μm U0126 for 30 min, and then stimulated with 10% serum. After 10 or 90 min, cells were washed twice with phosphate-buffered saline (PBS), lysed in an extraction buffer (20 mm Tris, pH 7.5, 150 mm NaCl, 10 mm β-glycerophosphate, 5 mm EGTA, 1 mmNa4P2O7, 5 mm NaF, 1 mm Na3VO4, 0.5% Triton X-100, and 1 mm DTT) supplemented with protease inhibitors (1 mm phenylmethylsulfonyl fluoride, 5 μg/ml leupeptin, 5 μg/ml pepstatin A, and 5 μg/ml aprotinin), and then subjected to immunoblotting. COS-1 cells were transfected with GFP-Bax and p35 together with various constructs using FuGENE6 transfection reagent (Roche Molecular Biochemicals) for 10 h. Cells were next treated with 1 μm staurosporine for 3 or 6 h and then subjected to immunoblotting. HeLa cells were grown on poly-d-lysine-coated coverslips in 6-well plates. Cells were incubated with or without 50 μmZ-VAD-CH2DCB in the absence of serum for 6 h, treated with or without 10 μm LY294002 or 10 μmU0126 for 30 min, and then stimulated with 10% serum. After 48 h, cells were pretreated with 100 nm MitoTracker CMXRos for 30 min, washed with PBS, and fixed with 3.7% formaldehyde in PBS for 10 min at room temperature. The coverslips were soaked with a blocking solution (PBS containing 5% bovine serum albumin and 0.4% Triton X-100) for 30 min and incubated with anti-Bax antibody for 1 h and then with Alexa-488 anti-rat IgG antibody for 30 min in the blocking solution. The cells exhibiting strong punctate staining of Bax, which overlapped with the distribution of MitoTracker CMXRos, were counted as the cells with mitochondrially localized Bax. These cells usually had very low levels of diffuse Bax staining in the cytoplasm. COS-1 cells were transfected with GFP-Bax and p35 together with various constructs and incubated for 10 h. Cells were then treated with 10 μm LY294002, 10 μm U0126, or staurosporine for the indicated times. The localization of GFP-Bax was detected by fluorescence microscope. COS-1 cells were transfected with various constructs for 1 day and treated with 1 μmstaurosporine for the indicated times. Then the cells were washed with PBS, scraped into an isotonic buffer (200 mm mannitol, 70 mm sucrose, 1 mm EDTA, 10 mm HEPES, pH 6.9, and 1 mm DTT) supplemented with the protease inhibitors described above, and homogenized using a Potter-Elvehjem homogenizer. Nuclei and unbroken cells were separated by centrifugation at 600 × g for 10 min. The supernatant was further centrifuged at 10,000 × g for 10 min to collect a heavy membrane pellet, which contained mitochondria. The pellet was washed with the isotonic buffer and resuspended into RIPA buffer (PBS containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and 1 mm DTT) supplemented with protease inhibitors, and the debris was then removed by a brief centrifugation. Recent studies have suggested that some survival-promoting conditions can suppress Bax translocation to mitochondria (20.Gilmore A.P. Metcalfe A.D. Romer L.H. Streuli C.H. J. Cell Biol. 2000; 149: 431-446Crossref PubMed Scopus (256) Google Scholar, 26.Putcha G.V. Deshmukh M. Johnson Jr., E.M. J. Neurosci. 1999; 19: 7476-7485Crossref PubMed Google Scholar). We first examined whether serum treatment can also suppress Bax translocation in HeLa cells because serum is known to promote survival. To examine this, intracellular localization of endogenous Bax was detected by immunocytochemistry. As shown in Fig. 1, Bax localized diffusely in the cytoplasm in the presence of serum. In contrast, serum deprivation induced Bax translocation from cytoplasm to mitochondria as revealed by localization of Bax at mitochondria visualized by a mitochondrial marker, MitoTracker CMXRos (Fig. 1, A and B). Addition of 50 μm Z-VAD-CH2DCB, a wide spectrum caspase inhibitor, had little effect on Bax translocation induced by serum deprivation (data not shown). These results demonstrated that serum is necessary for retaining Bax in the cytoplasm and that Bax translocation by serum deprivation is a caspase-independent event. It has been shown that the PI3K-Akt pathway and the MAPK pathway play important roles in growth factor-promoted cell survival by inhibiting several steps of apoptosis signaling depending on cell types and contexts (28.Datta S.R. Brunet A. Greenberg M.E. Genes Dev. 1999; 13: 2905-2927Crossref PubMed Scopus (3755) Google Scholar, 29.Bonni A. Brunet A. West A.E. Datta S.R. Takasu M.A. Greenberg M.E. Science. 1999; 286: 1358-1362Crossref PubMed Scopus (1697) Google Scholar, 30.Brunet A. Datta S.R. Greenberg M.E. Curr. Opin. Neurobiol. 2001; 11: 297-305Crossref PubMed Scopus (1026) Google Scholar, 31.Erhardt P. Schremser E.J. Cooper G.M. Mol. Cell. Biol. 1999; 19: 5308-5315Crossref PubMed Scopus (268) Google Scholar). The MAPK pathway has been shown to inhibit cytochrome c-induced caspase activation (31.Erhardt P. Schremser E.J. Cooper G.M. Mol. Cell. Biol. 1999; 19: 5308-5315Crossref PubMed Scopus (268) Google Scholar), but it is not known whether it also inhibits premitochondrial steps, including Bax translocation and cytochrome c release. On the other hand, active Akt has been shown to inhibit UV-induced cytochrome crelease in Rat1 fibroblasts (41.Kennedy S.G. Kandel E.S. Cross T.K. Hay N. Mol. Cell. Biol. 1999; 19: 5800-5810Crossref PubMed Scopus (602) Google Scholar), whereas PI3K activity has been reported to be dispensable for NGF-mediated suppression of Bax translocation in sympathetic neurons (45.Tsui-Pierchala B.A. Putcha G.V. Johnson Jr., E.M. J. Neurosci. 2000; 20: 7228-7237Crossref PubMed Google Scholar). Thus it remains unclear so far which molecules are responsible for growth factor suppression of Bax translocation to mitochondria. To examine whether PI3K or MEK (the activator of MAPK) mediates serum suppression of Bax translocation, HeLa cells were treated with LY294002, a PI3K inhibitor, or with U0126, a MEK inhibitor, in the presence of serum. Treatment with 10 μm LY294002 resulted in the promotion of Bax translocation to mitochondria (Fig. 2B) under the conditions in which phosphorylation of Akt, but not of MAPK, was effectively blocked (Fig. 2A). In contrast, treatment with 10 μmU0126, which effectively blocked MAPK phosphorylation under the same conditions, had no effect on Bax localization (Fig. 2, A andB). These results suggest that PI3K, but not MEK, is required for retaining Bax in the cytoplasm of serum-stimulated HeLa cells. Under the same experimental conditions, both serum deprivation and LY294002 treatment resulted in induction of apoptosis in the absence of caspase inhibitor as judged by pyknotic nuclei, whereas U0126 treatment did not (Fig. 2C, left panel). Moreover, most of the cells with mitochondrial endogenous Bax exhibited pyknotic nucleus, whereas most of the cells with cytoplasmic Bax displayed healthy nucleus (Fig. 2C, right panel). These results confirmed that Bax translocation correlated well with apoptosis in the system analyzed. To further examine whether PI3K activity is important for retaining Bax in the cytoplasm, we utilized a GFP-Bax fusion protein to monitor Bax localization in real time. In all experiments using GFP-Bax, p35, a pan-caspase inhibitor, was co-transfected to protect cells from undergoing apoptosis because ectopic expression of Bax results in activation of the caspase cascade, which might amplify the upstream apoptotic signals of Bax translocation (46.Gao C.F. Ren S. Zhang L. Nakajima T. Ichinose S. Hara T. Koike K. Tsuchida N. Exp. Cell. Res. 2001; 265: 145-151Crossref PubMed Scopus (97) Google Scholar). In control and U0126 (10 μm)-treated COS-1 cells, GFP-Bax typically displayed a diffuse, cytoplasmic localization (Fig. 3, A and B). In contrast, GFP-Bax gradually redistributed to mitochondria in response to LY294002 (10 μm) treatment (Fig. 3, A andB). These results suggest that endogenous PI3K activity, but not MEK activity, is necessary for retaining GFP-Bax in the cytoplasm in this system as well. We next investigated whether activation of PI3K is sufficient for inhibiting Bax translocation induced by staurosporine treatment. Staurosporine induced GFP-Bax translocation to mitochondria within several hours, but expression of p110CAAX, a membrane-targeted catalytic subunit of PI3K, resulted in a marked inhibition of Bax translocation (Fig. 3, A andC). In contrast, expression of active MEK with a S218D/S222D mutation had no effect on Bax translocation (Fig. 3, A andD). These results suggest that activation of PI3K is sufficient for retaining Bax in the cytoplasm of COS-1 cells. To dissect the downstream pathway of PI3K, we first tested whether Akt suppresses Bax translocation as Akt often mediates the effects of PI3K in promoting survival (28.Datta S.R. Brunet A. Greenberg M.E. Genes Dev. 1999; 13: 2905-2927Crossref PubMed Scopus (3755) Google Scholar, 30.Brunet A. Datta S.R. Greenberg M.E. Curr. Opin. Neurobiol. 2001; 11: 297-305Crossref PubMed Scopus (1026) Google Scholar). In fact, our results suggest that Akt plays an essential role in serum promotion of survival in the system analyzed (see Fig. 4D). We found that expression of active Akt, which had a myristylation sequence at the N terminus and lacked the pleckstrin homology domain, inhibited GFP-Bax translocation to mitochondria induced by staurosporine treatment (Fig. 4, A and B). In addition, a dominant negative Akt (3A), with a K179A/T308A/S473A mutation, enhanced GFP-Bax translocation moderately but reproducibly (Fig. 4C). A previous study has shown that expression of active Akt decreases the levels of Bax protein induced by nitric oxide in primary hippocampal neurons (47.Matsuzaki H. Tamatani M. Mitsuda N. Namikawa K. Kiyama H. Miyake S. Tohyama M. J. Neurochem. 1999; 73: 2037-2046PubMed Google Scholar). However, in this study, the levels of endogenous Bax and GFP-Bax did not alter by expression of Akt (Fig. 5), suggesting that Akt suppression of Bax translocation is not due to a reduction of Bax protein. In primary hippocampal neurons and IL-3-dependent Baf-3 cells, the PI3K-Akt pathway has been shown to induce Bcl-2 and Bcl-XL, which play critical roles in promoting survival of these cells (47.Matsuzaki H. Tamatani M. Mitsuda N. Namikawa K. Kiyama H. Miyake S. Tohyama M. J. Neurochem. 1999; 73: 2037-2046PubMed Google Scholar,48.Leverrier Y. Thomas J. Mathieu A.L. Low W. Blanquier B. Marvel J. Cell Death Differ. 1999; 6: 290-296Crossref PubMed Scopus (78) Google Scholar). It has recently been shown that expression of Bcl-2 is capable of inhibiting etoposide- and Fas-induced Bax translocation to mitochondria (17.Nomura M. Shimizu S. Ito T. Narita M. Matsuda H. Tsujimoto Y. Cancer Res. 1999; 59: 5542-5548PubMed Google Scholar, 18.Murphy K.M. Streips U.N. Lock R.B. J. Biol. Chem. 2000; 275: 17225-17228Abstract Full Text Full Text PDF PubMed Scopus (124) Google Scholar). Therefore, it is possible that Akt inhibition of Bax translocation is mediated by an increase in the levels of Bcl-2 and Bcl-XL proteins. However, the expression of active Akt did not alter the levels of Bcl-2 and Bcl-XL proteins under the conditions used in this study (Fig. 5), indicating that the suppression of Bax translocation by Akt is not due to increased expression of these antiapoptotic members of the Bcl-2 family.Figure 5Akt does not affect the protein levels of Bax, Bcl-2, and Bcl-XL. COS-1 cells were transfected with GFP-Bax and p35 together with various constructs and incubated for 10 h. The transfection efficiency was about 75%, measured by monitoring the expression of GFP-Bax. Cells were treated with 1 μm staurosporine for 3 h and then subjected to immunoblotting with anti-Bax, anti-Bcl-2, anti-Bcl-XL, and anti-tubulin antibodies.View Large Image Figure ViewerDownload Hi-res image Download (PPT) To further confirm the effects of Akt on Bax translocation, localization of endogenous Bax was assessed by subcellular fractionation after transfection of Akt constructs. As shown in Fig. 6, 6 h of staurosporine treatment in control (vector-transfected) cells increased the levels of Bax in the mitochondrial fraction. Twelve hours of staurosporine treatment resulted in redistribution of ∼30% of endogenous Bax to the mitochondrial fraction (Fig. 6). In contrast, little Bax protein was detected in the mitochondrial fraction when active Akt, but not kinase-negative (3A) Akt, was expressed in up to 12 h of staurosporine treatment (Fig. 6). The level of the VDAC in the mitochondrial fraction did not alter. These results suggest that active Akt inhibits endogenous Bax translocation to mitochondria. SGK, another downstream effector of PI3K-PDK1, is a kinase structurally related to Akt and has a substrate specificity very similar to Akt (33.Park J. Leong M.L. Buse P. Maiyar A.C. Firestone G.L. Hemmings B.A. EMBO J. 1999; 18: 3024-3033Crossref PubMed Scopus (489) Google Scholar). Because SGK also appears to play a role in promoting cell survival (33.Park J. Leong M.L. Buse P. Maiyar A.C. Firestone G.L. Hemmings B.A. EMBO J. 1999; 18: 3024-3033Crossref PubMed Scopus (489) Google Scholar, 44.Brunet A. Park J. Tran H. Hu L.S. Hemmings B.A. Greenberg M.E. Mol. Cell. Biol. 2001; 21: 952-965Crossref PubMed Scopus (724) Google Scholar), we examined the possible involvement of SGK in regulation of Bax localization. Expression of active SGK, with a S422D mutation, did not inhibit GFP-Bax translocation to mitochondria induced by staurosporine treatment (Fig. 7A). In addition, a dominant negative (2A) SGK, with a T256A/S422A mutation, did not enhance Bax translocation (Fig. 7B). We confirmed the expression of these SGK mutants by immunoblotting and phosphorylation of co-transfected FKHRL1, a substrate of SGK (Fig. 7C). Therefore, SGK appears not to mediate the effect of PI3K in suppressing Bax translocation. In sympathetic neurons, NGF inhibits premitochondrial steps of apoptosis signaling (26.Putcha G.V. Deshmukh M. Johnson Jr., E.M. J. Neurosci. 1999; 19: 7476-7485Crossref PubMed Google Scholar). Recently, Tsui-Pierchala et al.(45.Tsui-Pierchala B.A. Putcha G.V. Johnson Jr., E.M. J. Neurosci. 2000; 20: 7228-7237Crossref PubMed Google Scholar) have reported that PI3K activity is required for inhibiting an early death event proximal to c-Jun phosphorylation (most likely catalyzed by JNK) but not for inhibiting Bax translocation in NGF suppression of apoptosis. However, in COS-1 cells, activation of the PI3K-Akt pathway did not block staurosporine-induced JNK activation (Fig. 8) but did antagonize the staurosporine-induced Bax translocation (Fig. 4), suggesting that the main targets of the PI3K pathway in these two systems are different. Because our data indicate that activation of the PI3K-Akt pathway is sufficient for inhibiting Bax translocation, it is plausible that there is a redundant pathway in addition to the PI3K pathway downstream of NGF to block Bax translocation. The molecular mechanism of Bax subcellular redistribution is a matter of controversy. Previous reports have suggested that it involves conformational change of Bax induced by cytosolic alkalization and Bax dimerization (27.Khaled A.R. Kim K. Hofmeister R. Muegge K. Durum S.K. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 14476-14481Crossref PubMed Scopus (223) Google Scholar, 49.Gross A. Jockel J. Wei M.C. Korsmeyer S.J. EMBO J. 1998; 17: 3878-3885Crossref PubMed Scopus (973) Google Scholar). However, we found that GFP-Bax translocation was not induced by cytoplasmic pH values ranging between 6.6 and 8.6 when adjusted by nigericin, a proton ionophore, and extracellular pH (data not shown). In addition, it has been shown by NMR experiments that no conformational change of Bax can be detected within a potential intracellular pH range (50.Suzuki M. Youle R.J. Tjandra N. Cell. 2000; 103: 645-654Abstract Full Text Full Text PDF PubMed Scopus (916) Google Scholar). These data may suggest that there is no direct link between intracellular pH change and Bax translocation to mitochondria. Therefore, we do not assume that Akt regulates Bax localization via controlling intracellular pH. Thus far, we have not been able to determine which Akt target mediates its regulation of Bax. It is unlikely that Bax is a direct target of Akt because Bax does not contain the RXRXX(S/T) motif, the consensus sequence required for Akt phosphorylation (51.Alessi D.R. Caudwell F.B. Andjelkovic M. Hemmings B.A. Cohen P. FEBS Lett. 1996; 399: 333-338Crossref PubMed Scopus (556) Google Scholar). How Akt regulates Bax awaits further investigation. In conclusion, we show in this study that the PI3K-Akt pathway regulates Bax translocation to mitochondria in serum-stimulated HeLa and GFP-Bax-expressing COS-1 cells. This finding may account for why Akt inhibits cytochrome c release at a premitochondrial level. Because Bax is a key molecule regulating apoptosis, our results may have revealed an important nexus between apoptotic and survival signals. We thank Drs. Masayuki Miura, Richard Roth, Brian Hemmings, Anne Brunet, and Michael Greenberg for p35, Akt, SGK, and FKHRL1 plasmids and Jun Sunayama and members of the Gotoh laboratory for encouragement and helpful discussions.